https://crstoday.com/news/roches-purchase-of-spark-therapeutics-faces-further-delay-amid-scrutiny-from-us-uk-regulators/2476640/daily0.7https://crstoday.com/news/biogen-completes-acquisition-of-nightstar-therapeutics-for-approximately-800-million/2476641/daily0.7https://crstoday.com/news/eyepoint-pharmaceuticals-names-new-members-of-executive-leadership-team/2476642/daily0.7https://crstoday.com/news/sightlife-announces-100000-corneal-transplants-in-india-since-program-inception-in-2009/2476639/daily0.7https://crstoday.com/news/draper-james-and-vsp-eyes-of-hope-commit-nearly-4-million-to-fund-eye-care-and-eyewear-in-support-of-young-women/2476637/daily0.7https://crstoday.com/news/alcon-launches-art-focused-patient-campaign-in-honor-of-cataract-awareness-month/2476636/daily0.7https://crstoday.com/news/more-elderly-americans-dying-from-falls/2476634/daily0.7https://crstoday.com/news/medical-specialty-organizations-applaud-introduction-of-congressional-legislation-to-improve-oversight-and-transparency-in-prior-authorization/2476633/daily0.7https://crstoday.com/news/pioneering-ophthalmologist-patricia-bath-md-dies-at-76/2476632/daily0.7https://crstoday.com/news/eyenovia-enrolls-first-patient-in-phase-3-chaperone-study-for-progressive-myopia/2476629/daily0.7https://crstoday.com/news/ophtec-partners-with-vsa-in-argentina-to-commercialize-ophtecs-products/2476630/daily0.7https://crstoday.com/news/fda-wins-case-against-florida-stem-cell-clinic-that-harmed-three-womens-vision/2476631/daily0.7https://crstoday.com/news/report-goldman-sachs-unit-to-buy-capital-vision-services-in-2-7-billion-deal/2476625/daily0.7https://crstoday.com/news/seniors-with-vision-loss-experience-discrimination-depression/2476623/daily0.7https://crstoday.com/news/new-biomarker-research-builds-furthers-understanding-of-tebentafusp-mechanism-of-action-in-advanced-melanoma/2476624/daily0.7https://crstoday.com/news/lacrivera-introduces-the-vera180-synthetic-absorbable-lacrimal-plugs/2476620/daily0.7https://crstoday.com/news/the-maze-of-vision-loss-and-depression-in-older-adults/2476619/daily0.7https://crstoday.com/news/waveoptics-and-pegatron-demonstrate-air-glasses-prototype/2476618/daily0.7https://crstoday.com/news/vision-loss-linked-with-anxiety-depression-and-vice-versa/2476616/daily0.7https://crstoday.com/news/precision-medicine-to-prevent-glaucoma-related-blindness/2476617/daily0.7https://crstoday.com/news/study-3d-printed-artificial-corneas-similar-to-human-ones/2476615/daily0.7https://crstoday.com/news/ocular-therapeutix-announces-receipt-of-c-code-and-pass-through-payment-status-for-dextenza/2476614/daily0.7https://crstoday.com/news/quantel-medical-receives-ce-mark-for-dry-eye-diagnostic-platform-lacrystim-ipl/2476613/daily0.7https://crstoday.com/news/a-third-of-reviews-of-corneal-disease-treatments-not-reliable/2476611/daily0.7https://crstoday.com/news/ama-symptom-checking-health-app-often-wrong-in-diagnosing-eye-problems/2476612/daily0.7https://crstoday.com/news/lens-replacement-because-of-cataracts-may-improve-sleep/2476610/daily0.7https://crstoday.com/news/central-retinal-vein-occlusion-rarely-complicates-ulcerative-colitis/2476609/daily0.7https://crstoday.com/news/key-to-workplace-productivity-may-be-in-the-eyes/2476606/daily0.7https://crstoday.com/news/raz-mobility-launches-accessible-mobile-phone-for-individuals-with-impaired-vision/2476607/daily0.7https://crstoday.com/news/prominent-technologist-william-f-bill-stasior-joins-avellino-labs-executive-advisory-committee/2476608/daily0.7https://crstoday.com/news/immunocore-to-present-new-tebentafusp-imcgp100-data-in-advanced-melanoma-at-upcoming-2019-asco-annual-meeting/2476605/daily0.7https://crstoday.com/news/biophytis-files-registration-statement-for-proposed-initial-public-offering-in-the-united-states/2476604/daily0.7https://crstoday.com/news/wills-eye-hospital-research-suggests-glaucoma-patients-may-be-at-higher-risk-of-motor-vehicle-accidents-than-those-of-similar-age/2476601/daily0.7https://crstoday.com/news/ntc-grants-further-license-and-distribution-rights-to-santen-for-its-fixed-combination-dexamethasone-with-levofloxacin-in-south-east-asia/2476602/daily0.7https://crstoday.com/news/zeiss-ranked-best-company-in-germanys-public-value-atlas/2476600/daily0.7https://crstoday.com/news/ocular-therapeutix-otx-tp-intracanalicular-insert-fails-to-meet-phase-3-endpoint/2476598/daily0.7https://crstoday.com/news/study-probes-ods-attitudes-about-blue-light-blocking-devices/2476599/daily0.7https://crstoday.com/news/surgical-specialties-launches-caliber-ophthalmics-division-to-focus-on-global-growth-of-ophthalmic-surgical-procedures/2476597/daily0.7https://crstoday.com/news/jury-awards-allergan-just-48500-in-trial-over-imprimis-false-ads/2476595/daily0.7https://crstoday.com/news/alcon-reports-first-quarter-2019-trading-update/2476592/daily0.7https://crstoday.com/news/neuropathy-may-drive-dry-eye-in-migraine-patients/2476593/daily0.7https://crstoday.com/news/dexamethasone-injection-may-speed-iop-drop-in-angle-closure-glaucoma/2476594/daily0.7https://crstoday.com/news/novel-approaches-to-cataract-surgery-are-challenging-phaco-cost-may-determine-their-success/2476591/daily0.7https://crstoday.com/news/prevent-blindness-issues-call-for-nominations-for-the-2019-bonnie-strickland-champion-for-childrens-vision-award/2476590/daily0.7https://crstoday.com/news/patients-equally-pleased-with-different-keratoplasty-approaches/2476586/daily0.7https://crstoday.com/news/fda-oks-incobotulinumtoxina-xeomin-first-line-in-blepharospasm/2476587/daily0.7https://crstoday.com/news/glaucoma-research-foundation-kicks-off-the-catalyst-for-a-cure-vision-restoration-initiative/2476588/daily0.7https://crstoday.com/news/colorlite-colorblind-diagnostic-and-correction-system-now-available-in-the-united-states/2476585/daily0.7https://crstoday.com/news/allegro-ophthalmics-announces-positive-results-of-ex-us-proof-of-concept-trial-with-integrin-inhibitor-alg-1007-for-dry-eye-disease/2476583/daily0.7https://crstoday.com/news/zeiss-opens-cinema-lens-demo-center-in-los-angeles/2476584/daily0.7https://crstoday.com/news/physicians-patients-overwhelmingly-support-fda-distinct-biologic-naming-plan-suffixes-for-new-products/2476581/daily0.7https://crstoday.com/news/pecaa-launches-the-integrated-eye-care-initiative/2476579/daily0.7https://crstoday.com/news/tilak-healthcare-announces-exclusive-partnership-for-co-promotion-with-novartis-france/2476578/daily0.7https://crstoday.com/news/states-bring-price-fixing-suit-against-generic-drug-makers/2476576/daily0.7https://crstoday.com/news/regentree-initiates-arise-3-phase-3-trial-for-dry-eye-syndrome/2476577/daily0.7https://crstoday.com/news/clinical-study-showing-reduced-incidence-of-cystoid-macular-edema-with-omidria-presented-at-ascrs/2476575/daily0.7https://crstoday.com/news/jefferson-and-wills-eye-launch-worlds-first-center-focused-on-connections-between-the-eye-and-the-brain/2476574/daily0.7https://crstoday.com/news/cholesterol-lowering-drugs-tied-to-reduced-glaucoma-risk/2476570/daily0.7https://crstoday.com/news/optimo-medical-ag-wins-the-zkb-pioneer-prize-in-switzerland/2476568/daily0.7https://crstoday.com/news/hhs-finalizes-rule-requiring-manufacturers-disclose-drug-prices-in-tv-ads-to-increase-drug-pricing-transparency/2476569/daily0.7https://crstoday.com/news/novartis-to-acquire-dry-eye-drug-xiidra-in-deal-worth-up-to-5-3-billion/2476567/daily0.7https://crstoday.com/news/genentech-pivotal-phase-3-data-for-neuromyelitis-optica-spectrum-disorder-devics-disease/2476566/daily0.7https://crstoday.com/news/instrusafe-by-summit-medical-introduces-new-instrusafe-xl-transport-container/2476565/daily0.7https://crstoday.com/news/mati-therapeutics-phase-2-nepafenac-evolute-clinical-trial-results-show-significant-postoperative-pain-reduction/2476558/daily0.7https://crstoday.com/news/earlier-detection-of-diabetic-retinopathy-with-smartphone-ai/2476559/daily0.7https://crstoday.com/news/nick-mamalis-md-named-2019-ascrs-president-as-ascrs-unveils-new-branding/2476560/daily0.7https://crstoday.com/news/schwind-introduces-wisenet-intelligent-web-based-database/2476554/daily0.7https://crstoday.com/news/thomas-walters-md-presents-update-on-nicoxs-ncx-470-phase-2-clinical-study-in-podium-presentation-at-ascrs-2019/2476555/daily0.7https://crstoday.com/news/alcon-launches-advancements-to-the-centurion-vision-system-at-ascrs/2476556/daily0.7https://crstoday.com/news/eyenovia-announces-presentation-of-successful-phase-3-studies-at-the-ascrs/2476557/daily0.7https://crstoday.com/news/ellex-to-launch-innovative-new-ultrasound-technology-at-ascrs/2476552/daily0.7https://crstoday.com/news/the-healthcare-alliance-for-patient-safety-statement-in-response-to-ftc-proposed-contact-lens-rule/2476553/daily0.7https://crstoday.com/news/alcon-highlights-offerings-to-drive-practice-efficiency-and-excellence-at-ascrs/2476550/daily0.7https://crstoday.com/news/zeiss-announces-new-breakthroughs-in-digital-technology-and-high-resolution-imaging-at-ascrs/2476551/daily0.7https://crstoday.com/news/johnson-johnson-vision-highlights-new-data-on-personalized-vision-approach-with-tecnis-family-of-iols-and-highlights-progress-of-innovative-pipeline-at-ascrs/2476548/daily0.7https://crstoday.com/news/johnson-johnson-vision-showcases-the-rising-burden-of-myopia-new-contact-lens-and-surgical-technologies-at-arvo/2476549/daily0.7https://crstoday.com/news/allergan-to-present-two-podium-presentations-on-bimatoprost-sustained-release-sr-at-ascrs/2476546/daily0.7https://crstoday.com/news/leiters-now-integrated-into-besse-medicals-inventory-management-systems/2476547/daily0.7https://crstoday.com/news/nicox-presents-first-data-on-new-class-of-nitric-oxide-no-donating-compounds-for-glaucoma-at-arvo/2476545/daily0.7https://crstoday.com/news/biotech-healthcare-announces-korean-good-and-manufacturing-practices-approval/2476544/daily0.7https://crstoday.com/news/alcon-to-showcase-new-clinical-data-innovative-technology-at-ascrs/2476542/daily0.7https://crstoday.com/news/new-mobile-platform-records-patient-outcomes-after-cataract-surgery/2476543/daily0.7https://crstoday.com/news/sightglass-vision-presents-clinical-trial-data-from-novel-lenses-to-control-myopia/2476541/daily0.7https://crstoday.com/news/the-winning-pitch-challenge-featured-at-ascrs/2476539/daily0.7https://crstoday.com/news/allergan-ceo-saunders-wins-vote-to-keep-chairman-role/2476540/daily0.7https://crstoday.com/news/aerie-pharmaceuticals-matches-ascrs-foundation-fund-raising-to-provide-sight-saving-surgery/2476538/daily0.7https://crstoday.com/news/lensar-laser-system-receives-fda-clearance-to-perform-micro-radial-incisions-for-refractive-cataract-procedures/2476537/daily0.7https://crstoday.com/news/alcon-forms-strategic-alliance-to-bring-image-guided-biometry-to-the-cataract-refractive-suite/2476535/daily0.7https://crstoday.com/news/ophtec-receives-fda-approval-for-ringject-design-enhancements/2476536/daily0.7https://crstoday.com/news/sydnexis-announces-enrollment-of-first-patients-in-phase-3-myopia-staar-study-of-syd-101-in-children/2476532/daily0.7https://crstoday.com/news/atia-vision-closes-20m-in-series-d-financing-to-fund-accommodating-iol/2476533/daily0.7https://crstoday.com/news/ivantis-announces-3-year-results-from-fda-clinical-trial-demonstrating-long-term-reduction-of-severe-major-surgeries-for-glaucoma-patients/2476534/daily0.7https://crstoday.com/news/new-world-medical-recognizes-the-recipients-of-its-2019-humanitarian-project-award-health-outcomes-research-award-and-fellowship-awards/2476528/daily0.7https://crstoday.com/news/new-president-ceo-at-the-glaucoma-foundation/2476529/daily0.7https://crstoday.com/news/staar-surgical-announces-expanded-recommended-diopter-range-for-evo-visian-icl-in-germany-and-japan/2476531/daily0.7https://crstoday.com/news/avedro-completes-enrollment-in-pivotal-us-phase-3-epi-on-corneal-cross-linking-clinical-trial-for-progressive-keratoconus/2476526/daily0.7https://crstoday.com/news/jim-wachtman-joins-corneagen-as-chief-commercial-officer/2476527/daily0.7https://crstoday.com/news/clearside-biomedicals-suprachoroidal-space-injection-platform-featured-at-multiple-ophthalmology-and-gene-therapy-medical-meetings/2476524/daily0.7https://crstoday.com/news/ocular-science-launches-two-affiliates-to-focus-on-compounding-and-biologic-sectors-of-ophthalmic-market/2476525/daily0.7https://crstoday.com/news/avellino-labs-to-provide-corporate-and-technology-updates-at-ois-and-ascrs-in-san-diego/2476522/daily0.7https://crstoday.com/news/lighthouse-guild-says-integrating-vision-and-healthcare-services-is-essential-for-older-adults-in-presentation-arvo/2476521/daily0.7https://crstoday.com/news/lkc-technologies-launches-new-utas-systems-at-arvo/2476520/daily0.7https://crstoday.com/news/allegro-to-present-results-of-its-alg-1007-ex-us-trial-for-dry-eye-disease-at-ascrs/2476519/daily0.7https://crstoday.com/news/sight-sciences-announces-official-launches-of-tearcare-and-the-enhanced-next-generation-omni-system/2476517/daily0.7https://crstoday.com/news/imprimisrx-to-introduce-new-formulations-at-cataract-refractive-surgery-annual-meeting/2476518/daily0.7https://crstoday.com/news/lensgen-will-present-early-results-of-international-grail-study-at-ascrs/2476515/daily0.7https://crstoday.com/news/avedro-announces-comprehensive-educational-schedule-at-ascrs-annual-meeting/2476513/daily0.7https://crstoday.com/news/iridexs-micropulse-laser-technology-featured-in-several-glaucoma-and-retina-research-presentations/2476514/daily0.7https://crstoday.com/news/bausch-lomb-announces-update-from-antibiotic-resistance-monitoring-in-ocular-microorganism-armor-study/2476512/daily0.7https://crstoday.com/news/radiancetx-expands-team-to-develop-beta-ophthalmic-system/2476511/daily0.7https://crstoday.com/news/bausch-lomb-announces-new-scientific-analyses-featuring-surgical-and-pharmaceutical-products-will-be-presented-during-ascrs/2476509/daily0.7https://crstoday.com/news/implandata-gains-ce-mark-for-its-eyemate-system-for-keratoprosthesis/2476510/daily0.7https://crstoday.com/news/santen-and-glaukos-enter-into-collaboration-and-distribution-agreement-for-exclusive-distribution-of-the-microshunt-de-128-in-the-us/2476507/daily0.7https://crstoday.com/news/new-data-from-phase-3-teprotumumab-trial-shows-reduction-in-proptosis-or-eye-bulging-in-active-thyroid-eye-disease-ted/2476506/daily0.7https://crstoday.com/news/meiragtx-announces-upcoming-presentation-on-achromatopsia-gene-therapy-candidate-aav-cnga3-at-arvo-2019/2476504/daily0.7https://crstoday.com/news/new-scientific-and-clinical-analyses-regarding-bausch-lomb-surgical-and-pharmaceutical-products-to-be-presented-during-the-association-for-research-in-vision-and-ophthalmology-meeting/2476505/daily0.7https://crstoday.com/news/zeiss-launches-first-dual-speed-swept-source-oct-octa-at-arvo/2476503/daily0.7https://crstoday.com/news/presbia-abandons-flexivue-microlens-lays-off-all-but-3/2476501/daily0.7https://crstoday.com/news/novaliq-and-blp-management-group-establish-new-company-betaliq-to-leverage-eyesol-technology-to-treat-glaucoma/2476500/daily0.7https://crstoday.com/news/allegro-expands-its-anti-integrin-portfolio-with-new-dry-eye-disease-drug-candidate-alg-1007/2476499/daily0.7https://crstoday.com/news/allergan-to-showcase-new-data-at-arvo/2476496/daily0.7https://crstoday.com/news/ziemer-usa-sponsors-niios-usa-cornea-evening-2/2476495/daily0.7https://crstoday.com/news/study-microglia-play-a-vital-role-in-regulating-neuroinflammation-in-autoimmune-disease/2476491/daily0.7https://crstoday.com/news/ivantis-announces-publication-of-comparative-migs-clinical-trial-results/2476486/daily0.7https://crstoday.com/news/bausch-lomb-announces-new-divisional-leadership-in-the-us/2476487/daily0.7https://crstoday.com/news/foundation-fighting-blindness-to-host-annual-retinal-cell-gene-therapy-innovation-summit-before-arvo/2476488/daily0.7https://crstoday.com/news/akorn-receives-fda-approval-for-generic-loteprednol-etabonate/2476485/daily0.7https://crstoday.com/news/older-drivers-in-uk-are-being-forced-off-the-road-as-the-nhs-rations-cataract-operations-campaigners-warn/2476481/daily0.7https://crstoday.com/news/bausch-lomb-to-initiate-series-of-us-clinical-trials-for-technolas-teneo-excimer-laser/2476482/daily0.7https://crstoday.com/news/eric-bernabei-joins-avellino-labs-as-chief-sales-and-marketing-officer/2476483/daily0.7https://crstoday.com/news/lightmed-appoints-lee-walker-roberts-as-global-business-development-director/2476484/daily0.7https://crstoday.com/news/ucla-eliminating-routine-preoperative-tests-for-cataract-surgery-associated-with-cost-savings/2476480/daily0.7https://crstoday.com/news/us-military-develops-mobile-application-to-treat-eye-injuries/2476479/daily0.7https://crstoday.com/news/clearside-biomedical-announces-presentations-on-its-suprachoroidal-space-injection-platform-at-upcoming-medical-meetings/2476477/daily0.7https://crstoday.com/news/gensight-biologics-reports-positive-follow-up-results-of-phase-3-trial-in-lhon/2476475/daily0.7https://crstoday.com/news/fraunhofer-iap-developing-contact-lenses-with-medicine-and-sugar/2476476/daily0.7https://crstoday.com/news/results-of-lumega-z-data-to-be-presented-at-arvo/2476474/daily0.7https://crstoday.com/news/ophthotech-changes-name-to-iveric-bio-as-it-transitions-to-gene-therapy-company/2476473/daily0.7https://crstoday.com/news/proxy-advisory-firms-back-allergan-in-battle-with-dissident-shareholder-appaloosa/2476472/daily0.7https://crstoday.com/news/silktech-biopharmaceuticals-ind-submission-cleared-by-fda-phase-2-clinical-trial-initiated-for-patients-with-dry-eye-disease/2476469/daily0.7https://crstoday.com/news/oertli-upgrades-its-faros-compact-surgical-platform/2476470/daily0.7https://crstoday.com/news/novabay-pharmaceuticals-announces-new-partner-pharmacy-program/2476465/daily0.7https://crstoday.com/news/trial-highlights-5-year-performance-of-2-standalone-glaukos-istents-vs-topical-prostaglandin/2476466/daily0.7https://crstoday.com/news/gilbert-family-foundation-commits-11-million-to-combat-vision-loss-in-nf1-patients/2483607/daily0.7https://crstoday.com/news/us-ophthalmologists-push-to-remove-roadblocks-to-patients-access-to-medical-and-surgical-eye-care/2476461/daily0.7https://crstoday.com/news/texas-tech-medical-school-to-end-use-of-race-in-admissions/2476462/daily0.7https://crstoday.com/news/i-med-pharma-becomes-authorized-canadian-distributor-for-orcam-myeye-2/2476463/daily0.7https://crstoday.com/news/staar-surgical-celebrates-1-million-lens-milestone-for-implantable-collamer-lens/2476459/daily0.7https://crstoday.com/news/alnylam-regeneron-to-partner-for-rnai-treatments/2476457/daily0.7https://crstoday.com/news/alcon-debuts-as-independent-publicly-traded-company/2476453/daily0.7https://crstoday.com/news/allegro-ophthalmics-appoints-marc-carlson-and-rebecca-colbert-to-board-of-directors/2476454/daily0.7https://crstoday.com/news/data-published-on-acthar-gel-disease-status-and-utilization-patterns-in-uveitis-patients/2476455/daily0.7https://crstoday.com/news/aldeyra-therapeutics-to-present-phase-2b-dry-eye-disease-results-at-arvo/2476456/daily0.7https://crstoday.com/news/pecaa-community-raises-116000-for-optometry-giving-sight/2476452/daily0.7https://crstoday.com/news/james-mazzo-joins-board-of-directors-at-avellino-labs/2476451/daily0.7https://crstoday.com/news/improved-premium-iols-will-drive-growth-in-the-global-iol-market-over-the-next-5-years/2476449/daily0.7https://crstoday.com/news/nidek-launches-the-ark-f-ar-f-auto-refractometer/2476446/daily0.7https://crstoday.com/news/nidek-launches-the-rt-6100-refractor-and-ts-610-tabletop-refraction-system/2476447/daily0.7https://crstoday.com/news/clearside-biomedical-appoints-dr-george-lasezkay-as-interim-ceo/2476448/daily0.7https://crstoday.com/news/raynor-host-surgical-skills-program-to-surgical-luminaries/2476445/daily0.7https://crstoday.com/news/avedros-corneal-cross-linking-procedure-now-covered-by-65-coverage-policies/2476444/daily0.7https://crstoday.com/news/radiology-techs-assisting-with-fluoroscopy-may-risk-cataracts/2476441/daily0.7https://crstoday.com/news/eurazeo-capital-to-acquire-dorc-from-montagu/2476442/daily0.7https://crstoday.com/news/study-vision-loss-has-significant-impact-on-use-of-hospital-resources-and-costs-for-older-patients/2476440/daily0.7https://crstoday.com/news/istent-inject-device-lowers-iop-after-cataract-surgery-in-glaucoma-patients/2476438/daily0.7https://crstoday.com/news/arvo-foundation-announces-new-mallinckrodt-uveitis-research-fellowship/2476437/daily0.7https://crstoday.com/news/a-soft-spot-for-stem-cells-helps-cornea-healing/2476436/daily0.7https://crstoday.com/news/testosterone-may-underlie-rare-blindness-condition-in-women/2476435/daily0.7https://crstoday.com/news/ocutrx-vision-technologies-receives-second-patent-for-augmented-reality-glasses-eye-tracking-technology/2476434/daily0.7https://crstoday.com/news/righteye-builds-database-of-one-billion-eye-tracking-data-points/2476433/daily0.7https://crstoday.com/news/alcon-announces-timothy-stonesifer-as-chief-financial-officer/2476432/daily0.7https://crstoday.com/news/bausch-lomb-announces-us-launch-of-lotemax-sm-0-38-for-treatment-of-postoperative-inflammation-and-pain/2476431/daily0.7https://crstoday.com/news/ocular-therapeutix-announces-supplemental-nda-accepted-by-fda-for-dextenza/2476429/daily0.7https://crstoday.com/news/alcon-adds-topical-local-anesthetic-alcaine-0-5-15ml-to-its-ophthalmic-portfolio/2476426/daily0.7https://crstoday.com/news/iridex-provides-update-on-world-glaucoma-congress-activities/2476427/daily0.7https://crstoday.com/news/novabay-pharmaceuticals-announces-investments-of-5-million-to-support-us-avenova-commercialization-strategy/2476424/daily0.7https://crstoday.com/news/johnson-johnson-to-air-first-commercial-for-prescription-drug-that-also-discloses-its-cost/2483626/daily0.7https://crstoday.com/news/arkansas-secures-expanded-scope-of-practice/2479581/daily0.7https://crstoday.com/news/heidelberg-engineering-introduces-the-gmpe-hood-glaucoma-report-for-spectralis-oct/2479582/daily0.7https://crstoday.com/news/fda-prepares-for-possible-device-shortages-after-gas-leaks-lead-to-closure-of-sterilization-plant/2479583/daily0.7https://crstoday.com/news/iot-introduces-evolens-machine-learning-system-designed-to-increase-patient-satisfaction-over-time/2479585/daily0.7https://crstoday.com/news/first-subjects-enrolled-in-clinical-study-to-evaluate-safety-and-efficacy-of-omni-surgical-system-for-migs-procedures/2476422/daily0.7https://crstoday.com/news/orasis-announces-initiation-of-phase-2b-clinical-study-of-csf-1-for-the-treatment-of-presbyopia/2476421/daily0.7https://crstoday.com/news/i-pen-osmolarity-system-now-available-in-brazil-through-partnership-with-drycom/2476420/daily0.7https://crstoday.com/news/mary-lynch-md-receives-innovator-award-from-the-american-glaucoma-society/2476419/daily0.7https://crstoday.com/news/aldeyra-therapeutics-announces-positive-topline-results-from-the-phase-3-alleviate-trial-in-patients-with-allergic-conjunctivitis/2476416/daily0.7https://crstoday.com/news/regenerx-and-lees-pharm-to-accelerate-rgn-259-development-in-china/2476417/daily0.7https://crstoday.com/news/johnson-johnson-visions-investigational-antihistamine-releasing-contact-lens-demonstrates-positive-phase-3-results/2476418/daily0.7https://crstoday.com/news/quantel-medical-receives-fda-approval-for-absolu-ultrasound-platform/2476415/daily0.7https://crstoday.com/news/allergan-agrees-to-split-ceo-chairman-roles-at-next-leadership-transition/2476413/daily0.7https://crstoday.com/news/implandata-gains-ce-mark-for-next-generation-eyemate-system/2476411/daily0.7https://crstoday.com/news/unitedhealthcare-launches-national-vision-laboratory-network-relationship-with-essilor-labs/2476409/daily0.7https://crstoday.com/news/eyepromise-introduces-screen-shield-teen-all-natural-eye-vitamin-for-screen-time-protection/2476410/daily0.7https://crstoday.com/news/novartis-plans-for-alcon-spin-off-on-april-9-2019/2476408/daily0.7https://crstoday.com/news/topcon-to-present-new-solution-for-oct-and-data-management-at-vee-2019/2476407/daily0.7https://crstoday.com/news/study-examines-using-re-esterified-omega-3-and-maqui-berry-in-combination-as-a-treatment-for-dry-eye-disease/2476402/daily0.7https://crstoday.com/news/study-excess-hormones-could-cause-a-condition-that-can-lead-to-blindness-in-women/2476403/daily0.7https://crstoday.com/news/user-friendly-visual-acuity-chart-shows-good-agreement-with-existing-charts/2476405/daily0.7https://crstoday.com/news/aerie-pharmaceuticals-initiates-netarsudil-ophthalmic-solution-phase-2-clinical-trial-in-japan/2476406/daily0.7https://crstoday.com/news/vsp-global-names-steve-baker-president-of-vsp-ventures/2476398/daily0.7https://crstoday.com/news/optovue-launches-new-angiowellness-scan-at-vision-expo-east/2476399/daily0.7https://crstoday.com/news/5-people-tested-positive-at-free-initial-screenings-for-glaucoma-at-saifee-hospital/2476400/daily0.7https://crstoday.com/news/q-biomed-and-mannin-research-to-develop-gdf15-biomarker-glaucoma-diagnostic-kit/2476396/daily0.7https://crstoday.com/news/synergeyes-launches-tangible-hydra-peg-coating-on-synergeyes-vs-scleral-lens/2476394/daily0.7https://crstoday.com/news/lilliana-vazquez-to-moderate-vision-expos-eye2eye-series-with-common/2476392/daily0.7https://crstoday.com/news/nicox-initiates-phase-2-trial-of-ncx-4251-in-blepharitis/2476393/daily0.7https://crstoday.com/news/american-academy-of-optometry-announces-peter-scott-as-new-executive-director/2476390/daily0.7https://crstoday.com/news/fluoride-can-cause-degenerative-eye-diseases-study-shows/2476388/daily0.7https://crstoday.com/news/gensight-biologics-to-present-72-week-data-from-the-reverse-phase-3-trial-of-gs010/2476389/daily0.7https://crstoday.com/news/acucela-signs-agreement-to-develop-a-compact-oct-for-nasas-deep-space-missions/2476385/daily0.7https://crstoday.com/news/alcon-announces-acquisition-of-powervision/2476387/daily0.7https://crstoday.com/news/new-study-shows-an-eye-scan-can-detect-signs-of-alzheimers-disease/2476384/daily0.7https://crstoday.com/news/nicox-signs-agreement-for-zerviate-in-china-for-up-to-e17-million-in-milestone-payments-plus-royalties/2476381/daily0.7https://crstoday.com/news/former-lens-butler-executives-have-launched-boxsee-contact-lens-subscription-service/2476382/daily0.7https://crstoday.com/news/clinical-trials-show-safety-and-efficacy-of-kala-pharmaceuticals-inveltys-for-bid-treatment-of-postoperative-inflammation-and-pain/2476380/daily0.7https://crstoday.com/news/clinical-study-demonstrates-long-term-iop-reduction-with-the-omni-surgical-system-predicate-device-trab-360-in-migs/2476378/daily0.7https://crstoday.com/news/ivantis-announces-24-month-results-of-landmark-prospective-randomized-comparative-migs-clinical-trial/2476379/daily0.7https://crstoday.com/news/allergan-to-present-new-data-on-bimatoprost-sr-at-the-american-glaucoma-society-annual-meeting/2476377/daily0.7https://crstoday.com/news/coburn-technologies-introduces-new-spin-coater-with-dual-coating-technology-velocity-2d/2476376/daily0.7https://crstoday.com/news/study-confirms-long-term-efficacy-and-safety-profile-of-glaukos-istent-in-combination-with-cataract-surgery/2476375/daily0.7https://crstoday.com/news/dompe-receives-industry-innovation-award-for-oxervate-eye-drops-for-neurotrophic-keratitis/2476372/daily0.7https://crstoday.com/news/national-cancer-institute-director-ned-sharpless-to-cecome-acting-fda-head/2476373/daily0.7https://crstoday.com/news/prevent-blindness-announces-recipient-of-2019-jenny-pomeroy-award-for-excellence-in-vision-and-public-health/2476374/daily0.7https://crstoday.com/news/aerie-pharmaceuticals-receives-fda-approval-of-rocklatan-for-reduction-of-iop/2476371/daily0.7https://crstoday.com/news/eyepoint-pharmaceuticals-announces-us-commercial-launch-of-dexycu/2476370/daily0.7https://crstoday.com/news/q-biomed-licenses-novel-biomarker-for-monitoring-glaucoma-severity-and-progression-from-washington-university/2476369/daily0.7https://crstoday.com/news/clemson-eye-integrates-two-greenville-eye-care-practices-into-its-network/2476368/daily0.7https://crstoday.com/news/topcon-introduces-the-is-100-ophthalmic-unit/2476366/daily0.7https://crstoday.com/news/japans-health-ministry-approves-worlds-first-trials-for-using-ips-cells-to-treat-corneal-disease/2476363/daily0.7https://crstoday.com/news/major-league-soccer-all-star-alecko-eskandarian-to-speak-at-annual-nora-conference/2476364/daily0.7https://crstoday.com/news/low-birth-weight-tied-to-altered-eye-anatomy-in-adulthood/2476361/daily0.7https://crstoday.com/news/zeiss-receives-fda-clearance-for-epithelial-thickness-mapping-for-cirrus-hd-oct/2476359/daily0.7https://crstoday.com/news/gottliebs-quick-goodbye-triggers-investor-panic-biopharma-bewilderment/2476360/daily0.7https://crstoday.com/news/study-results-show-neuroptics-npi-200-pupillometer-provides-early-warning-of-neurological-damage/2476358/daily0.7https://crstoday.com/news/telemedicine-eye-screenings-help-detect-glaucoma/2476356/daily0.7https://crstoday.com/news/2019-bressler-prize-awarded-to-vladimir-kefalov-phd-for-outstanding-accomplishments-in-vision-science-research/2476357/daily0.7https://crstoday.com/news/myco-industries-debuts-ab-max-advanced-for-treatment-of-anterior-blepharitis/2476354/daily0.7https://crstoday.com/news/fda-grants-breakthrough-device-designation-to-concussion-assessment-device/2476351/daily0.7https://crstoday.com/news/bausch-health-completes-acquisition-of-certain-assets-of-synergy-pharmaceuticals/2476352/daily0.7https://crstoday.com/news/eyecare-services-partners-names-new-ceo-and-adds-two-other-executives/2476353/daily0.7https://crstoday.com/news/fda-issues-recall-of-raindrop-near-vision-inlay/2476350/daily0.7https://crstoday.com/news/fda-chief-scott-gottlieb-to-resign/2476349/daily0.7https://crstoday.com/news/biogen-to-acquire-gene-therapy-company-nightstar-therapeutics-in-800-million-deal/2479586/daily0.7https://crstoday.com/news/macula-may-not-benefit-from-a-blue-light-filtering-intraocular-lens/2476346/daily0.7https://crstoday.com/news/new-data-from-alcon-shows-that-compliant-contact-lens-wear-can-improve-practice-outcomes/2479590/daily0.7https://crstoday.com/news/survey-physicians-generate-an-average-of-2-4-million-a-year-per-hospital/2479591/daily0.7https://crstoday.com/news/penetrating-keratoplasty-effective-for-corneal-complications-of-shingles/2479592/daily0.7https://crstoday.com/news/the-american-optometric-association-highlights-the-importance-of-early-intervention-through-annual-eye-exams/2479593/daily0.7https://crstoday.com/news/staar-surgical-announces-strategic-cooperation-agreement-with-vista-oftalmologos/2479594/daily0.7https://crstoday.com/news/aldeyra-therapeutics-provides-update-on-ophthalmic-programs/2476256/daily0.7https://crstoday.com/news/bausch-health-to-acquire-certain-assets-of-synergy-pharmaceuticals/2476257/daily0.7https://crstoday.com/news/pharmaceutical-executives-field-questions-at-us-senate-hearing-over-drug-pricing/2476258/daily0.7https://crstoday.com/news/topivert-announces-first-patients-dosed-in-theia-1-phase-2b-3-study-of-dry-eye-disease-treatment/2476259/daily0.7https://crstoday.com/news/novartis-issues-summary-financial-information-for-the-alcon-eye-care-business-ahead-of-shareholder-vote/2476260/daily0.7https://crstoday.com/news/oyster-point-raises-93-million-to-support-the-clinical-development-of-novel-treatment-for-dry-eye-disease/2476261/daily0.7https://crstoday.com/news/ziemer-usa-names-brad-hurt-vice-president-of-business-development/2476263/daily0.7https://crstoday.com/news/rayner-launches-new-eye-drop-formulations-for-dry-eye/2476264/daily0.7https://crstoday.com/news/nidek-launches-upgraded-angioscan-oct-angiography-software/2476265/daily0.7https://crstoday.com/news/eyenovia-announces-confirmatory-results-from-second-microstat-phase-3-registration-study-for-mydriasis/2476266/daily0.7https://crstoday.com/news/fda-approves-bausch-lombs-lotemax-sm-for-the-treatment-of-postoperative-inflammation-and-pain/2476267/daily0.7https://crstoday.com/news/roche-acquires-spark-therapeutics-in-4-3-billion-deal/2476268/daily0.7https://crstoday.com/news/wsj-roche-nears-deal-to-buy-spark-therapeutics-for-close-to-5-billion/2476269/daily0.7https://crstoday.com/news/eyebrain-medical-and-idoc-announce-partnership-to-bring-neurolens-to-idoc-independent-optometrists/2476270/daily0.7https://crstoday.com/news/health-burden-of-glaucoma-has-risen-worldwide/2476271/daily0.7https://crstoday.com/news/morphic-therapeutic-enters-into-integrin-research-and-development-collaboration-with-jjs-janssen/2476272/daily0.7https://crstoday.com/news/allergan-responds-to-public-shareholder-letter/2476274/daily0.7https://crstoday.com/news/ophtecs-preloaded-capsular-tension-ring-ringject-receive-approval-in-china/2476275/daily0.7https://crstoday.com/news/alembic-pharmaceuticals-announces-fda-approval-for-glaucoma-treatment-acetazolamide-extended-release-capsules/2476277/daily0.7https://crstoday.com/news/righteye-introduces-functional-vision-eyeq-automated-test/2476278/daily0.7https://crstoday.com/news/abbvies-humira-adalimumab-approved-by-health-canada-to-treat-pediatric-patients-with-chronic-noninfectious-anterior-uveitis/2476279/daily0.7https://crstoday.com/news/bruder-introduces-hygienic-eyelid-solution/2476280/daily0.7https://crstoday.com/news/bausch-health-acquires-eton-pharmaceuticals-em-100-investigational-eye-drop-for-the-treatment-of-itchy-eyes-associated-with-allergies/2476282/daily0.7https://crstoday.com/news/essilor-vision-foundation-collaborates-with-government-of-maharashtra-to-support-a-free-vision-care-program-for-2-5-million-children-in-need/2476283/daily0.7https://crstoday.com/news/alcon-debuts-ilux-mgd-treatment-system-for-personalized-therapy-for-dry-eye-disease-at-seco/2476284/daily0.7https://crstoday.com/news/college-of-optometrists-in-vision-development-nora-issue-joint-recommendation-for-optometric-evaluation-following-brain-injury/2476285/daily0.7https://crstoday.com/news/maculogix-relocates-to-larger-headquarters-in-harrisburg-pennsylvania-to-accommodate-growth/2476286/daily0.7https://crstoday.com/news/unitedhealthcare-vision-plans-rank-highest-in-customer-satisfaction-in-j-d-power-report/2476287/daily0.7https://crstoday.com/news/diabetes-eye-exam-frequency-in-us-is-alarmingly-low/2476288/daily0.7https://crstoday.com/news/vsy-biotechnology-and-carl-zeiss-meditec-settle-legal-disputes/2476289/daily0.7https://crstoday.com/news/leiters-and-mobius-therapeutics-enter-into-national-sales-and-marketing-agreement-for-mitosol/2476290/daily0.7https://crstoday.com/news/registration-now-open-for-neuro-optometric-rehabilitation-association-meeting/2476291/daily0.7https://crstoday.com/news/new-medscape-report-finds-more-than-one-in-three-doctors-are-burned-out/2476292/daily0.7https://crstoday.com/news/eyenovia-confirms-expanded-microprost-phase-3-indication-to-enroll-broad-patient-population-for-iop-lowering/2476294/daily0.7https://crstoday.com/news/heidelberg-oct2-module-successfully-installed-at-the-international-space-station/2476295/daily0.7https://crstoday.com/news/zeiss-and-cbm-partner-to-open-new-training-center-for-ophthalmologists-in-pune-india/2476296/daily0.7https://crstoday.com/news/bausch-lomb-receives-510k-clearance-for-use-of-the-tangible-hydra-peg-custom-contact-lens-coating-on-several-lenses/2476297/daily0.7https://crstoday.com/news/melt-pharmaceuticals-improves-patent-estate-for-sublingual-non-opioid-pain-and-sedation-formulations/2476298/daily0.7https://crstoday.com/news/ophtecs-precizon-presbyopic-iol-with-continuous-transitional-focus-ctf-optic-now-patented-in-the-us/2476299/daily0.7https://crstoday.com/news/pr3vent-completes-series-a-financing-led-by-infocus-capital-partners/2476301/daily0.7https://crstoday.com/news/retreatment-with-a-single-tearcare-treatment-continues-to-provide-relief-for-patients-with-dry-eye-disease/2476302/daily0.7https://crstoday.com/news/topivert-announces-publication-of-data-from-its-positive-phase-2-study-of-top1630-in-dry-eye-disease/2476303/daily0.7https://crstoday.com/news/arise-3-phase-3-clinical-trial-of-the-rgn-259-for-the-treatment-of-dry-eye-syndrome-is-initiated-by-regentree/2476304/daily0.7https://crstoday.com/news/our-artificial-cornea-breakthrough-could-lead-to-self-assembling-organs/2476305/daily0.7https://crstoday.com/news/optical-and-ophthalmology-cloud-solutions-provider-kide-systems-becomes-topcon-healthcare-solutions-emea/2476307/daily0.7https://crstoday.com/news/topcon-healthcare-solutions-and-oculo-form-global-partnership/2476308/daily0.7https://crstoday.com/news/cei-vision-partners-adds-virginia-eye-consultants-as-fifth-partner/2476310/daily0.7https://crstoday.com/news/eu-5-ophthalmic-market-will-top-10-billion-in-2023/2476311/daily0.7https://crstoday.com/news/conditions-treated-with-cannabis-often-lack-good-evidence/2476312/daily0.7https://crstoday.com/news/the-ascrs-announces-2019-ophthalmology-hall-of-fame-inductees/2476313/daily0.7https://crstoday.com/news/laser-vision-correction-market-growth-continues-for-third-consecutive-year/2476315/daily0.7